1. Pink Sheet
  2. >>Market Access

Indication-Based Pricing Sparks Interest In UK

Experts Advocate Flexible Drug Pricing Models For NHS

 
• By Vibha Sharma

Different prices for different medical conditions treated by the same drug and tying drug prices to the benefits they deliver are some of the recommendations made by a cross-sector expert panel to improve patient access to innovative cancer medicines.

Pills_Stamped_GBP
Better Prescribing Data Is Needed To Support Flexible Drug Pricing In UK • Source: Shutterstock

The UK’s National Health Service should explore flexible drug pricing models for new cancer treatments, such as paying different prices for the same drug depending on the indications (i.e. particular conditions) it is approved to treat, a cross-discipline group of experts has recommended.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Market Access

More from Pink Sheet

Another Regeneron CRL Prompts Regulatory Operations Questions

 
• By Alaric DeArment

CEO Len Schleifer said during the company’s first quarter earnings call that most of the complete response letters the company has received related to third-party suppliers, not efficacy or safety.

UK Mandates Unmodified Standardized Contracts To Speed Clinical Trial Set-Up

 
• By Vibha Sharma

The policy expectation that the model clinical trial agreements are used without modification is in line requests from industry and the NHS/HSC.

Canada’s HTA Agency Reveals How To Submit AI-Driven Evidence

 
• By Neena Brizmohun

Recognizing that the evidence it receives in applications for health technology assessments will increasingly be informed by artificial intelligence, the CDA-AMC has clarified its expectations for companies that use AI methods in the generation and/or reporting of evidence.